Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

We assessed the efficacy of combined temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma in a phase II single-institution trial. Twenty-four patients were enrolled. Temozolomide (150 mg/m(2)/day for 7 days every other week) was administered with concomitant thalid...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyar, Michelle S., Hesdorffer, Mary, Keohan, Mary Louise, Jin, Zhezhen, Taub, Robert N.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583339/
https://www.ncbi.nlm.nih.gov/pubmed/19043564
http://dx.doi.org/10.1155/2008/412503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583339/
https://www.ncbi.nlm.nih.gov/pubmed/19043564
http://dx.doi.org/10.1155/2008/412503

Ejemplares similares